A serum panel of three microRNAs may serve as a possible biomarker for Kidney renal clear cell carcinoma

Abstract

Background: Approximately 75 percent of cases of renal cell carcinoma, also known as kidney renal clear cell carcinoma (KIRC), are diagnosed during procedures to identify renal cell carcinoma (RCC). Although non-invasive radiological techniques are widely applied in the diagnoses of KIRC, ˃ 50% of KIRCs are currently detected incidentally. The presence of microRNA (miRNA) in serum has the potential to serve as a non-invasive diagnostic biomarker for KICC. Method: In the three-part trial, there were a total of 224 participants, 112 of them were KIRC patients (KIRCs), while the other 112 were healthy controls (NCs). RT-qPCR was utilized so that we could evaluate the level of miRNA expression in both KIRCs and NCs. ROC curves and the area under the ROC curve (AUC) were utilized in order to make a prediction regarding the usefulness of serum miRNAs for KIRC diagnosis. In addition, we performed survival analysis and bioinformatics with our research. Results: We discovered that miR-1-3p, miR-129-5p, miR-146b-5p, miR-187-3p and miR-200a-3p showed statistically significant differences when compared to NCs. It was determined that a panel consisting of three microRNAs (miR-1-3p, miR-129-5p and miR-146b-5p) had an AUC of 0.895, with a 95% confidence interval ranging from 0.848 to 0.942. CREB5 may be a potential target gene of the panel in the GEPIA database. According to the survival analysis, the overexpression of miR-146b-5p was indicative of a poorer prognosis for KIRC patients. Conclusions:There is a significant possibility that the three-miRNA panel in the serum could serve as non-invasive indicators for KIRC.